Have a feature idea you'd love to see implemented?
Let us know!
STRO Sutro Biopharma Inc
Price (delayed)
$2.53
Market cap
$208.62M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.61
Enterprise value
$58.05M
Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.
Highlights
STRO's EPS is up by 45% YoY and by 12% from the previous quarter
The company's debt fell by 35% YoY and by 6% QoQ
The quick ratio has contracted by 41% YoY and by 10% from the previous quarter
The equity has declined by 27% since the previous quarter
Key stats
What are the main financial stats of STRO
Market
Valuations
Earnings
Shares outstanding
82.46M
Market cap
$208.62M
Enterprise value
$58.05M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.86
Price to sales (P/S)
1.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.36
Revenue
$160.96M
EBIT
-$79.46M
EBITDA
-$67.41M
Free cash flow
-$109.2M
Per share
Balance sheet
Liquidity
EPS
-$1.61
Free cash flow per share
-$1.33
Book value per share
$1.36
Revenue per share
$1.96
TBVPS
$5.51
Total assets
$451.83M
Total liabilities
$340.61M
Debt
$24.86M
Equity
$111.22M
Working capital
$274.49M
Debt to equity
0.22
Current ratio
3.09
Quick ratio
3.01
Net debt/EBITDA
2.23
Margins
Efficiency
Dividend
EBITDA margin
-41.9%
Gross margin
100%
Net margin
-77%
Operating margin
-80.8%
Return on assets
-27.3%
Return on equity
-97%
Return on invested capital
-29.2%
Return on capital employed
-24.8%
Return on sales
-49.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
STRO stock price
How has the Sutro Biopharma stock price performed over time
Intraday
-5.24%
1 week
-26.67%
1 month
-30.49%
1 year
-5.95%
YTD
-41.03%
QTD
-26.88%
Financial performance
How have Sutro Biopharma's revenue and profit performed over time
Revenue
$160.96M
Gross profit
$160.96M
Operating income
-$130.04M
Net income
-$123.95M
Gross margin
100%
Net margin
-77%
The company's net margin has surged by 78% YoY but it fell by 4.8% QoQ
STRO's operating margin has soared by 78% YoY but it is down by 29% QoQ
STRO's operating income is up by 28% year-on-year but it is down by 23% since the previous quarter
STRO's net income is up by 28% YoY
Growth
What is Sutro Biopharma's growth rate over time
Valuation
What is Sutro Biopharma stock price valuation
P/E
N/A
P/B
1.86
P/S
1.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.36
STRO's EPS is up by 45% YoY and by 12% from the previous quarter
The equity has declined by 27% since the previous quarter
The stock's price to book (P/B) is 23% less than its last 4 quarters average of 2.4 and 15% less than its 5-year quarterly average of 2.2
The stock's price to sales (P/S) is 82% less than its 5-year quarterly average of 7.2 and 28% less than its last 4 quarters average of 1.8
Sutro Biopharma's revenue has decreased by 5% QoQ
Efficiency
How efficient is Sutro Biopharma business performance
STRO's ROS has soared by 86% YoY and by 19% from the previous quarter
STRO's return on invested capital has surged by 50% year-on-year and by 13% since the previous quarter
STRO's return on assets is up by 34% year-on-year
Sutro Biopharma's ROE has increased by 6% YoY
Dividends
What is STRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for STRO.
Financial health
How did Sutro Biopharma financials performed over time
STRO's total assets is 33% greater than its total liabilities
The quick ratio has contracted by 41% YoY and by 10% from the previous quarter
Sutro Biopharma's current ratio has decreased by 40% YoY and by 9% from the previous quarter
The company's debt is 78% lower than its equity
Sutro Biopharma's debt to equity has decreased by 35% YoY but it has increased by 29% from the previous quarter
The company's debt fell by 35% YoY and by 6% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.